CXA-10

Phase 2Small molecule

CComplexa, Inc.

CXA-10 is one of 27 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaWithdrawn

AsthmaPhase 2

Withdrawn

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

CXA-10

CComplexa, Inc.

Phase 2

2 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Asthma

NCT03762395

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension3 trials

Oral CXA-10 in Pulmonary Arterial Hypertension

Terminated·GGladwin, Mark, MD·Phase 2·NCT04125745·1 enrolled

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Terminated·CComplexa, Inc.·Phase 2·NCT03449524·69 enrolled

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

Terminated·CComplexa, Inc.·Phase 2·NCT04053543·33 enrolled

Asthma2 trials

Anti-Inflammatory Lipid Mediators in Asthma

Withdrawn·SSally E. Wenzel MD·Phase 2·NCT03680976

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT03762395·60 enrolled

Interaction1 trial

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

Completed·CComplexa, Inc.·Phase 1·NCT02547402·10 enrolled

Obese1 trial

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

Completed·CComplexa, Inc.·Phase 1·NCT02460146·43 enrolled

Focal Segmental Glomerulosclerosis1 trial

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Completed·CComplexa, Inc.·Phase 2·NCT03422510·33 enrolled

3 more indications

Kidney Injury1 trial

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

Completed·CComplexa, Inc.·Phase 1·NCT02248051·12 enrolled

Oral1 trial

Oral CXA-10 Study in Healthy Volunteers

Completed·CComplexa, Inc.·Phase 1·NCT02313064·40 enrolled

Unspecified1 trial

Study of CXA-10 in Healthy Volunteers

Completed·CComplexa, Inc.·Phase 1·NCT02127190·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for CXA-10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CXA-10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CXA-10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Complexa, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CComplexa, Inc.

CXA-10

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Pulmonary Arterial Hypertension3 trials

Asthma2 trials

Interaction1 trial

Obese1 trial

Focal Segmental Glomerulosclerosis1 trial

Kidney Injury1 trial

Oral1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News